Exercise Intervention for Chemotherapy-Induced Peripheral Neuropathy
India282 participantsStarted 2024-10-01
Plain-language summary
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of chemotherapy that can negatively impact patients' functional status and quality of life. This study was conducted in two phases among oncology patients receiving chemotherapy at a tertiary care teaching hospital in Chennai, India. Phase I used a descriptive survey design to determine the prevalence of CIPN. Phase II employed a randomized controlled experimental design to evaluate the effectiveness of a structured exercise program in reducing CIPN symptoms among patients with mild to moderate CIPN. Eligible participants were randomly assigned to intervention and control groups. The intervention group received education and supervised exercises involving lower and upper extremity movements, while the control group received routine care. Outcomes were assessed using the Chemotherapy-Induced Peripheral Neuropathy Assessment Scale before and after a 21-day intervention period.
Who can participate
Age range
18 Years – 78 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age greater than 18 years
* Receiving chemotherapy
* Diagnosed with mild or moderate chemotherapy-induced peripheral neuropathy
* Willing to participate and provide informed consent
Exclusion Criteria:
* Pre-existing peripheral neuropathy unrelated to chemotherapy (e.g., diabetic neuropathy).
* Uncontrolled diabetes mellitus.
* Significant cardiovascular disease.
* Severe musculoskeletal disorders.
* Contraindications to exercise, including recent surgery, bone metastases, or severe anemia.
* Severe mobility limitations.
* Severe mental health conditions affecting participation.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial studied whether exercise can reduce the severity of chemotherapy-induced peripheral neuropathy — do you know if the results have been published yet, and what did they find about whether exercise actually helped?
2Since this trial is already completed, are there exercise-based programs for peripheral neuropathy that you'd recommend I try now, based on what studies like this one have shown?
3What types or intensity of exercise were typically used in trials like this one, and would any of those be safe for me given my current chemotherapy regimen and overall health?
4If my neuropathy symptoms are already significant, would you suggest I focus on exercise as part of my care, or are there other treatments — like medication or physical therapy — that might be a better starting point for me?
5Is there another active clinical trial studying exercise or other non-drug approaches for chemotherapy-induced peripheral neuropathy that I might be eligible to discuss with you?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Severity of Chemotherapy-Induced Peripheral Neuropathy
Timeframe: Baseline and Day 21
Trial details
NCT IDNCT07635901
SponsorSri Ramachandra Institute of Higher Education and Research